Indian Chronic Lymphocytic Leukemic market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Chronic lymphocytic leukemia (CLL) is the most common leukemia found in adults. It’s a type of cancer that starts in cells that become white blood cells (called lymphocytes) in the bone marrow. The cancer (leukemia) cells start in the bone marrow but then go into the blood. The incidence rate of CLL in India is 0.41 per 100 000 (10 times lower than that in the United States). Men are inflicted by this condition 2 – 3 times, more than a women. Incidence rates for all categories of leukemia are higher among males in comparison to females. The incidence of Chronic Lymphocytic Leukemia increases significantly among people who are older than 50 years of age. Majority of the affected patients are over 60 years. The disease is not prevalent among children.
The market size drivers for the growth of Chronic Lymphocytic Leukemic cancer diagnostics are expected to propel by rise in the number of cigarette smokers, & growing R&D investments and reimbursement policies. Factors such as rising incidence of Chronic Lymphocytic Leukemic cancer and growing research activities for developing novel treatments coupled with increasing government funding for the cancer treatment research are driving the Chronic Lymphocytic Leukemic cancer treatment market.